Finland and Norway Biotech: Polaris the merger product of Targovax and Oncos Therapeutics | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Redefining Early Stage Investments (RESI) Conference @JPM, San Francisco, CA, JANUARY 12, 2016, Marine’s Memorial Club & Hotel

People with blood type O have been reported to be protected from coronary heart disease, cancer, and have lower cholesterol levels. »

Finland and Norway Biotech: Polaris the merger product of Targovax and Oncos Therapeutics

January 11, 2016 by 2012pharmaceutical

Finland and Norway Biotech: Polaris the merger product of Targovax and Oncos Therapeutics

Reporter: Aviva Lev-Ari, PhD, RN

SEE MAP for Europe BioTech

http://labiotech.eu/map/

SOURCE

http://labiotech.eu/polaris-a-new-nordic-leader-in-immuno-oncology/

Posted in CE Mark & Global Regulatory Affairs: process management and strategic planning - GCP, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment | Leave a Comment

Leave a ReplyCancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 9,319 other subscribers
Recent Posts
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: